Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Fineline Cube Mar 2, 2026
Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Fineline Cube Mar 2, 2026
Company Drug

AstraZeneca’s Fasenra Gains FDA Approval for Pediatric Severe Asthma Treatment

Fineline Cube Apr 12, 2024

AstraZeneca (AZ; NASDAQ: AZN) has secured an indication extension from the U.S. Food and Drug...

Company Drug

Qilu Pharmaceutical Gets NMPA Green Light for Generic Romiplostim for ITP Treatment

Fineline Cube Apr 12, 2024

The National Medical Products Administration (NMPA) in China has granted marketing approval to Qilu Pharmaceutical...

Company Drug

Suzhou Zelgen Receives NMPA Approval for Jacktinib Cream Trial in Vitiligo Patients

Fineline Cube Apr 12, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval from...

Company Drug

Haisco Pharmaceutical Gets NMPA Green Light for HSK31858 COPD Trial

Fineline Cube Apr 12, 2024

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it...

Company Deals

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in a $4.9 Billion Deal

Fineline Cube Apr 12, 2024

In a multibillion-dollar deal within the biotechnology sector, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a leader...

Company Drug

Teva’s Ajovy Achieves Positive Results in Phase III Migraine Prevention Trial in China

Fineline Cube Apr 12, 2024

Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has announced positive results from a...

Company Deals Medical Device

LargeV Instrument’s IPO on STAR Board Halted Following Filing and Sponsorship Withdrawal

Fineline Cube Apr 12, 2024

The initial public offering (IPO) of LargeV Instrument Corp., Ltd to the Shanghai Stock Exchange’s...

Company Drug

Enhertu Shows 58.3% Response Rate in Phase II Lung Cancer Study, AstraZeneca and Daiichi Sankyo Report

Fineline Cube Apr 11, 2024

The Phase II DESTINY-Lung05 study results for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate co-developed by...

Company Drug

Yantai Dongcheng Secures Approval for Phase I Study of 68Ga-LNC1007 in Singapor

Fineline Cube Apr 11, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has received approval from the Health Sciences...

Company Drug

Sino Biopharmaceutical to Present Phase II Data for Garsorasib at AACR 2024

Fineline Cube Apr 11, 2024

Sino Biopharmaceutical Ltd. (HKG: 1177) announced that it will present the results of a Phase...

Company Deals

STRATA Skin Sciences Renews Exclusive Distribution Deals in China and Japan

Fineline Cube Apr 11, 2024

STRATA Skin Sciences Inc. (NASDAQ: SSKN), a U.S.-based dermatology and plastic surgery firm, has announced...

Company Medical Device

Aptar Pharma Secures NMPA Approval for Airless Drug Delivery System in Chin

Fineline Cube Apr 11, 2024

Aptar Pharma, a U.S.-based company, announced that its Mezzo+ CS (China Support) Airless dispensing solution...

Company Policy / Regulatory

BIO’s Chief Lobbyist Nick Shipley Resigns Amid Controversy Over WuXi AppTec

Fineline Cube Apr 11, 2024

Nick Shipley, the chief lobbyist for the U.S.-based Biotechnology Innovation Organization (BIO), has resigned from...

Company Drug Medical Device

Roche Secures CE Mark for Ventana HER2 Test, Enhancing Access to AstraZeneca’s Enhertu

Fineline Cube Apr 11, 2024

Roche (SWX: ROG), based in Switzerland, has received CE marking from the European Commission (EC)...

Company Drug

Pfizer Reports Positive Phase III Results for RSV Vaccine Abrysvo in Younger Adults

Fineline Cube Apr 11, 2024

Pfizer (NYSE: PFE) has announced interim results from a Phase III trial evaluating its respiratory...

Company

Boehringer Ingelheim’s Shanghai Unit Secures EMA and FDA Approval for Biopharmaceutical Supply

Fineline Cube Apr 11, 2024

Germany-based Boehringer Ingelheim has announced that its Shanghai-based Contract Manufacturing Organization (CMO), Boehringer Ingelheim Biopharmaceuticals...

Company Deals

Sanofi Extends Collaboration with Nurix Therapeutics, Targeting STAT6 in Type 2 Inflammation

Fineline Cube Apr 11, 2024

France’s Sanofi (NASDAQ: SNY) has announced an extension of its 2019 collaboration with Nurix Therapeutics...

Company Deals

Genesis MedTech Secures Hundreds of Millions in Funding to Boost R&D and Manufacturing in China

Fineline Cube Apr 11, 2024

Singapore-based medical device company Genesis MedTech has raised “hundreds of millions” of renminbi in a...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Clinical Study of SHR-A2102 and SHR-8068 in Advanced Tumors

Fineline Cube Apr 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has received approval from the National Medical Products...

Company

Novartis Announces Layoffs to Streamline Operations and Boost Portfolio Value

Fineline Cube Apr 10, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) is gearing up for a strategic restructuring that will...

Posts pagination

1 … 338 339 340 … 628

Recent updates

  • Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy
  • HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline
  • Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug
  • GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC
  • InnoCare’s Zurletrectinib Wins Priority Review for Pediatric NTRK Tumors – Next‑Gen TRK Inhibitor Expands Label
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

Company Drug

HealZen’s BTK Inhibitor HZ-A-018 Wins NMPA Approval for CSU Phase II – Expands Autoimmune Pipeline

Company Drug

Ribo Life Science’s PCSK9 siRNA RBD7022 Enters Phase III – Qilu Pharma Advances Cholesterol‑Lowering Drug

Company Drug

GenFleet’s GFH375 Wins CDE Breakthrough Therapy Designation – Oral KRAS G12D Inhibitor for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.